Interview Ron van Schaik
Interview Ron van Schaik 20 mei 2021 'Iedereen heeft recht op een DNA-paspoort' Ron van Schaik Professor farmacogenetica Nederland is vooralsnog het enige land ter wereld waar patiënten bij de apotheek medicatie op maat kunnen krijgen op basis van hun DNA-profiel.
Forward Thinking An Interview with Ron Van Schaik PMF Features
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. ML Becker, LE Visser, RHN van Schaik, A Hofman, AG Uitterlinden,. Diabetes 58 (3), 745-749. , 2009. 313.
Ronald van Schaik Werf&
Prof. Dr. Ron van Schaik, PhD is a registered European specialist Laboratory medicine (2003) and a Full Professor of Pharmacogenetics (2013). He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, The Netherlands.
Ron van Schaik Associate Professor Erasmus MC XING
Prof. Dr. Ron van Schaik (PhD, FACB) is a registered European Specialist Laboratory Medicine and a Full Professor of Pharmacogenetics. He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, and is Director of the International (IFCC) Expert-center for Pharmacogenetics.
Ron van Schaik Leadership and Change consultant Boertien Vergouwen Overduin LinkedIn
prof. dr. Ron van Schaik Full professor, Erasmus MC, Clinical Chemistry https://orcid.org/0000-0003-1864-2151 Overview Fingerprint Network Research output (402) Similar Profiles (1) Supervised Work (5) If you made any changes in Pure these will be visible here soon. Fingerprint Dive into the research topics where Ron van Schaik is active.
Ron van Schaik Owner CGA Web Design LinkedIn
Ron H.N. van Schaik Full Professor Pharmacogenetics / Head Dept Clinical Chemistry / Past-President European Society Pharmacogenomics & Personalised Therapy (ESPT) 10mo
20181103_19Wintersun Ron van Schaik Flickr
Pharmacogenetics International Expertcenter - Prof. Dr. Ron H.N. van Schaik - Erasmus MC Research group/lab | Prof. Dr. Ron H.N. van Schaik Pharmacogenetics International Expertcenter Research is aimed at discovery and implementation of DNA analysis for personalizing drug therapy About our research group/lab Our research Key Publications
Ron SCHAIK Professor Erasmus MC, Rotterdam Erasmus MC Department of Clinical Chemistry (AKC)
Andrews, Louise ; Hesselink, Dennis; van Schaik, Ron et al. / A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.In: British Journal of Clinical Pharmacology. 2019 ; Vol. 85, No. 3. pp. 601-615.
Ron van Schaik • BioTech Pharma Summit
Ron SCHAIK | Cited by 18,852 | of Erasmus MC, Rotterdam (Erasmus MC) | Read 541 publications | Contact Ron SCHAIK
Ron H van Schaik, Professor, Erasmus University, Rotterdam, the Netherlands (3) YouTube
Ron van Schaik Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the liver, responsible for the oxidative metabolism of ∼50% of clinically prescribed drugs.
5. SLOVENSKI KONGRES KLINIČNE KEMIJE IN LABORATORIJSKE MEDICINE
Dive into the research topics where Ron van Schaik is active. These topic labels come from the works of this person. Together they form a unique fingerprint. 1 Similar Profiles; Circulating Tumor DNA Medicine & Life Sciences 100%. Cytochrome P-450 CYP2D6 Medicine & Life Sciences 87%.
Nieuwe inzichten helpen patiënt in strijd tegen depressie Siemens Healthineers Nederland
Contact External Profile About Introduction Publications Other positions Profile of R.H.N. van Schaik, PhD, Erasmus MC, Rotterdam, Professor Pharmacogenetics.
Faculty of Pharmaceutical Sciences Ron van Schaik, PhD Michael Smith Laboratories
New insights were provided by the esteemed keynote speakers, André G. Uitterlinden, Ron H.N. van Schaik, Roos van Westrhenen and all other speakers, Lone Fisker, Jordan Moore, Tiffany Morris, PhD.
Prof. Dr. Ron H.N. van Schaik Laboratoriumspecialist Erasmus MC
Simple Summary Although the introduction of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) has significantly improved the overall survival (OS) in patients with metastatic.
Ron H van Schaik, Professor, Erasmus University, Rotterdam, the Netherlands (5) YouTube
Ron H.N. van Schaik's Post Ron H.N. van Schaik Full Professor Pharmacogenetics / Head Dept Clinical Chemistry / Past-President European Society Pharmacogenomics & Personalised Therapy (ESPT)
Interview Ron van Schaik
Prof van Schaik has given over 200 invited lectures and participates on multiple national and international advisory committees on pharmacogenetics In 2001, he received the Ortho Clinical Diagnostics Award for Outstanding Research, in 2009 the AACC Outstanding Speaker Award, and in 2010 the AACC/Mol Pathology Award for Outstanding Scientific Research.
